Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹23.29 Cr (-23% YoY, +62% QoQ), EBITDA margin 16.9%, PAT ₹1.63 Cr (-67% YoY). Sequential recovery; CRAMS and new products progressing.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Q2FY27 revenue ₹23.29 Cr (-23% YoY, +62% QoQ), EBITDA margin 16.9%, PAT ₹1.63 Cr (-67% YoY). Sequential recovery; CRAMS and new products progressing.
Shree Ganesh Remedies released a press release on Q2 and H1 FY27 unaudited results, with Q2 revenue of ₹23.29 Crore, down 23% year-on-year. PAT fell 67% to ₹1.63 Crore.
Shree Ganesh Remedies' board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Revenue from operations for the half year was Rs 3,765.47 lakhs, down from Rs 5,498.29 lakhs a year earlier.
Shree Ganesh Remedies Ltd notified BSE of a board meeting on October 31, 2026, to consider unaudited standalone and consolidated results for the quarter ended September 2026. Trading window remains closed until 48 hours after the results declaration.
Shree Ganesh Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Shree Ganesh Remedies Ltd has announced the resignation of Mr. Aditya Vikrambhai Patel as Company Secretary and the appointment of Ms. Akanksha as his successor.
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Limited has issued the notice for its 31st Annual General Meeting scheduled for September 12, 2026. Shareholders will consider key resolutions and director appointments.
Shree Ganesh Remedies Limited has filed its Annual Report for FY 2025-26. It also includes the notice for the 31st Annual General Meeting on September 12, 2026.
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies announced its Q1FY27 financial results. Revenue from operations stood at ₹14.36 Crore, with a PAT of ₹1.12 Crore.
Shree Ganesh Remedies Limited has appointed M/s. M. I. Prajapati & Associates LLP as the company's Cost Auditor for a term of 12 months.
Shree Ganesh Remedies Ltd reported revenue from operations of ₹14.4 Cr (-41.7% YoY) and net profit of ₹1.1 Cr (-67.6% YoY) for Q1 FY27.